Moneycontrol PRO

business

Ranbaxy ban: Outsourcing an option, negative EBIDTA seen

Ranbaxy‘s Toansa plant supplies 70 percent of US-based Ohm Laboratories‘ Active Pharmaceutical Ingredients (API) requirement. This in turn means the company will soon have to go in for outsourcing, incurring a huge costs.

first published: Jan 24, 2014 10:44 am

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347